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Increased Risk of Type 2 Diabetes in Elderly Twins
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OBJECTIVE—Genetic susceptibility, low birth weight (LBW),
and aging are key etiological factors in the development of type
2 diabetes. LBW is common among twins. It is unknown whether
twin status per se is associated with risk of type 2 diabetes, and
valid concordance rates of type 2 diabetes in twins on a lifetime
perspective are lacking.
RESEARCH DESIGN AND METHODS—A clinical study was
done on a population-based cohort of same-sex elderly monozy-
gotic (MZ) and dizygotic (DZ) twins (n  297) and singleton
control subjects (C) (n  71) including measures of anthropom-
etry and glucose tolerance. In addition, type 2 diabetes incidence
cases in twins (n 626) and singletons (n 553) were identified
through the National Diabetes Register.
RESULTS—Twins were more abdominally obese, insulin resis-
tant, and glucose intolerant, as evidenced by a higher A1C (%)
(means  SD) (MZ: 6.0  1.0, DZ: 5.8  0.7, C: 5.6  0.3, P 
0.004) and 120-min post–oral glucose tolerance test plasma
glucose levels (in mmol/l) (MZ: 8.6  4.6, DZ: 8.4  3.9, C: 6.8 
2.4, P  0.003) compared with singletons. Importantly, twins had
a higher prevalence of type 2 diabetes (MZ: 17.5% [95% CI
14.4–20.6], DZ: 15.7% [13.1–18.3], C: 5.6% [3.0–8.2], P  0.03)
together with a 60% higher incidence rate of type 2 diabetes
compared with singletons. Cumulative concordance rates of type
2 diabetes to the age of 84 years were similar among elderly MZ
(0.76 [0.68–0.84]) and DZ (0.71 [0.63–0.78]) twins.
CONCLUSIONS—Twin status per se is associated with abdom-
inal obesity, insulin resistance, and increased prevalence of type
2 diabetes in elderly twins. The data support a quantitatively
significant impact of the fetal environment as opposed to genet-
ics on risk of type 2 diabetes. Diabetes 58:1350–1355, 2009
Type 2 diabetes is a complex disease with amultifactorial etiology. The finding of higherconcordance rates among monozygotic (MZ)compared with dizygotic (DZ) twins in some
(1–3) but not all (4) twin studies has been considered as
strong evidence of a significant genetic component in type
2 diabetes. Further support has been provided by the
recent identification of a number of type 2 diabetes–
associated genes in the genome-wide association studies
(5,6). However, the combined effect of these type 2 diabe-
tes susceptibility genes accounts for 10% of the popula-
tion risk of the disease, and even for the most significant
type 2 diabetes susceptibility genes, such as the TCF7L2
gene, the predominant proportion of the carriers of risk
alleles will not develop type 2 diabetes on a lifetime
perspective (5).
Low birth weight is another known risk factor for type 2
diabetes and is more common in twins compared with
singletons (7). In accordance with the “fetal origin hypoth-
esis” (8–10), we have demonstrated elevated plasma glu-
cose and insulin profiles during an oral glucose challenge
in MZ compared with DZ twins (11). A more recent study
of nondiabetic elderly twins (12) provided some mecha-
nistic explanation in such that monozygosity was associ-
ated with reduced peripheral insulin sensitivity.
Furthermore, twin status per se was related to increased
hepatic glucose production (i.e., hepatic insulin resis-
tance) compared with elderly age-matched singleton con-
trol subjects (12). Whether these metabolic differences
within and between twins and singletons have any clinical
importance, as reflected in an increased risk of developing
overt type 2 diabetes, is currently unknown.
Age is an important etiological factor in type 2 diabetes
and has been shown to play a key role in unmasking the
unfavorable metabolic effects associated with adverse
fetal environment (13,14). In addition, age may be equally
important in modulating the genetic influence on type 2
diabetes; however, valid concordance rates of type 2
diabetes among the oldest twins are lacking. We hypothe-
sized that age may change the relative genetic effect on
type 2 diabetes as well as the effect of twin and zygosity
status on type 2 diabetes. Therefore, we performed a
10-year follow-up study of a population-based cohort of
elderly twins examined in 1995 (4,11) together with an
age-matched cohort of singleton control subjects.
RESEARCH DESIGN AND METHODS
This study represents a 10-year follow-up study of a population-based cohort
of elderly MZ and same-sex DZ twins (n 626) previously investigated in 1995
(4,11). Among these twins, 122 subjects (MZ, n  43 [16.6%]; DZ, n  79
[21.5%]), P  0.17) were deceased in 2005 when the follow-up study was
performed. Of the remaining 504 twins, 207 twins (MZ, n  91; DZ, n  116)
either did not wish to or were refrained from participation by the investigator
because of severe current or chronic illness, including cancer or severe
dysfunction of major organ systems. Although the clinical examination was
performed in close proximity to the homes of the participants, and transpor-
tation was provided, some subjects were not able to participate solely due to
reduced mobility. A total of 297 twins (MZ, n  125, of which 49 were full
pairs; DZ, n  172, of which 55 were full pairs) equivalent to 57.9 and 59.7%
of eligible MZ and DZ twins, respectively, participated in a subsequent clinical
examination. One additional MZ twin (cotwin to a twin participating in the
baseline 1994–1995 study) was included in the follow-up study. The final
sample of twins undergoing the clinical examination was 298 twins. The
singleton control subjects (n  71) were recruited among spouses to the
participating twins.
All spouses (n  553) of the 626 twins included in the baseline study were
identified through the Civil Registration System. Both twins and spouses were
followed for death through the Civil Registration System and occurrence of
type 2 diabetes through the Danish National Diabetes Register (NDR) (15).
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The register-based diagnosis of type 2 diabetes is based on hospital diagnosis
(in- or outpatient) and/or consecutive plasma glucose measures performed in
the primary health care sector (15).
The study was approved by the regional ethical committees and was
conducted according to the principles of the Helsinki Declaration.
The clinical examination included a standardized 75-g oral glucose toler-
ance test (OGTT) performed after an overnight fast. Blood samples were
taken before and 30, 60, and 120 min after glucose ingestion. Plasma glucose
and insulin concentrations were analyzed as previously described (4,11). The
fasting blood samples were furthermore analyzed for serum triglycerides and
HDL cholesterol using commercial kits from Boerhinger Mannheim (Mann-
heim, Germany).
Weight and height were measured with the subject in lightweight clothes
without shoes, and BMI was calculated. Waist circumference was measured
using a soft tape on standing subjects midway between the lowest rib and the
iliac crest. Hip circumference was measured over the widest part of the gluteal
region, and the waist-to-hip ratio (WHR) was calculated accordingly.
The same type 2 diabetes diagnostic criteria were used in both the baseline
and follow-up study: 1) known type 2 diabetes, that is, diagnosis of diabetes
after the age of 40 years and current treatment with antidiabetic agents or diet,
and/or 2) a fasting plasma glucose concentration 7.8 mmol/l and/or 2-h
post-OGTT plasma glucose concentration 11.1 mmol/l. Impaired glucose
tolerance (IGT) was defined as fasting plasma glucose concentration 7.8
mmol/l and 2-h post-OGTT plasma glucose concentrations between 7.8 and
11.1 mmol/l.
Areas under the curve (AUC) for plasma glucose, insulin, and C-peptide
were calculated for the initial 30-min period and for the entire 120-min period
using the trapezoidal method. Insulin resistance was assessed using the
homeostasis model assessment (HOMA) (16) and whole-body insulin sensi-
tivity indexes (17). As measurements for insulin secretion, we calculated the
HOMA -cell function and insulinogenic indexes, i.e., the ratio between the
30-min increment in insulin and glucose concentration after oral glucose
loading.
Statistical methods. The distributions of zygosity and sex among nonpar-
ticipating and participating twin pairs as well as the prevalence of type 2
diabetes and IGT were compared by 2 tests. The comparisons of continuous
variables between participating and nonparticipating MZ and DZ twins and
singletons were performed with a mixed model (proc mixed in SAS, version
9.1, SAS Institute). We adjusted for the intra–twin-pair relationship in the
analyses by including a random-effect term for twin-pair membership with
zygosity-specific variance and a fixed-effect term for zygosity in the model.
Raw data are presented as means  SD.
Cumulative proband-wise concordance rates of type 2 diabetes from age 45
to 84 years were estimated for MZ and DZ twins and compared with a 2 test
(18,19). Proband-wise concordance rate expresses the risk of disease among
co-twins of affected twins and is comparable to the recurrence risk in other
groups of relatives and in the general population.
The incidence rates of diabetes from the NDR (15) were tabulated by
zygosity (MZ, DZ, spouse), sex and age, and calendar time in 1-year classes
using the SAS-macro %Lexis for splitting follow-up time, and modeled using a
Poisson regression model with smooth effects of age and calendar time, and
effects of sex and zygosity in three classes (MZ, DZ, spouse). Prevalence of
type 2 diabetes from the Danish National Diabetes Register as of 31 December
2005 was tabulated by sex, zygosity, and age.
RESULTS
Clinical characteristics of MZ and DZ twins at base-
line according to participation in the follow-up study.
Both MZ and DZ twins participating in the follow-up study
were younger, taller, and had lower post-OGTT plasma
glucose and insulin levels at baseline than those not
participating. Moreover, the participating DZ had lower
WHR than nonparticipating DZ twins (Table 1). Finally, the
distribution of type 2 diabetes, IGT, and NGT baseline was
different in the twins participating in the follow-up study
among both MZ (P  0.008) and DZ (P  0.001) twins
(Table 1). There was no difference in participation accord-
ing to glucose tolerance status between MZ and DZ (P 
0.76).
Follow-up study glucose profiles. During the 10-year
follow-up period, fasting plasma glucose levels (means 
SD, mmol/l) were unchanged within both MZ (MZ1995:
6.1  1.9 vs. MZ2005: 6.1  1.8, P  0.87), and DZ (DZ1995:
5.9 1.4 vs. DZ2005: 5.8 1.0, P 0.78) twins. In MZ twins,
the 30-min plasma glucose level was unchanged (MZ1995:
9.8  2.5 vs. MZ2005: 9.6  2.6, P  0.39), whereas there
was a significant increase over time within DZ twins
(DZ1995: 9.0  2.3 vs. DZ2005: 9.6  2.1, P  0.0001).
Accordingly, the increment in 30-min plasma glucose
TABLE 1
Baseline clinical characteristics of 626 MZ and DZ elderly twins stratified according to whether they were deceased or alive and
eligible for the follow-up study conducted in 2005
MZ DZ
Deceased No follow-up Follow-up Deceased No follow-up Follow-up
n (M/F) 43 (23/20) 91 (37/54) 125 (71/54) PMZ 79 (50/29) 116 (51/65) 172 (75/97) PDZ
Age at baseline (years) 69.1 3.7 68.1 3.8 65.5 4.9 68.3 3.5 66.9 5.1 64.7 5.3
Anthropometry
Height (cm) 162.8 8.5 164.5 9.7 167.9 9.7 0.004 167.2 10.4 164.8 9.1 167.2 8.4 0.02
Weight (kg) 67.9 14.0 70.0 13.9 74.3 13.6 0.12 71.6 15.2 71.2 13.3 72.4 12.9 0.27
BMI (kg/m2) 25.5 4.2 25.8 4.6 26.3 4.3 0.55 25.6 4.8 26.2 4.7 25.8 3.9 0.28
Waist (cm) 90.1 14.1 88.9 12.6 91.1 11.5 0.84 92.2 13.8 89.7 12.3 87.7 12.4 0.13
Hip (cm) 100.3 8.7 102.5 9.0 102.7 7.8 0.45 101.6 8.9 102.8 9.5 103.0 8.1 0.52
WHR 0.90 0.10 0.87 0.08 0.89 0.08 0.31 0.91 0.08 0.87 0.09 0.85 0.10 0.01
OGTT: glucose (mmol/l)
0 min 6.3 1.4 6.1 1.5 6.1 1.9 0.78 6.3 1.9 6.2 1.8 5.9 1.4 0.10
30 min 10.4 2.3 9.8 2.3 9.8 2.5 0.36 10.6 3.3 9.8 2.7 9.0 2.3 0.001
120 min 9.0 4.3 8.5 4.6 7.4 4.1 0.06 8.7 4.7 8.3 4.6 7.0 3.6 0.004
OGTT: insulin (pmol/l)
0 min 52.9 31.9 45.3 26.3 45.9 24.2 0.43 44.8 25.3 48.9 37.6 41.7 22.5 0.05
30 min 309.4 197.3 324.2 353.7 324.5 196.1 0.36 304.0 273.1 320.8 285.4 259.5 167.9 0.08
120 min 418.6 389.4 371.1 513.1 253.7 194.3 0.05 301.8 306.0 345.7 338.8 245.7 223.3 0.01
Glucose tolerance status
Type 2 diabetes/IGT/NGT
(%) 23.3/27.9/48.8 17.6/23.1/59.3 8.1/16.0/75.9 0.008 21.5/30.4/48.1 13.8/25.9/60.3 5.8/16.9/77.3 0.001
Data are means  SD unless otherwise stated. P value expresses the level of statistical significance for the comparison between the three
groups (deceased, no follow-up, and follow-up) (ANOVA) within MZ (PMZ) and DZ (PDZ) twins, respectively. The analyses have been adjusted
for sex.
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levels over the 10-year follow-up period was significantly
higher in DZ twins (MZ: 0.18  2.2; DZ: 0.6  1.8, P 
0.006). There was a significant deterioration in glucose
tolerance with age with an increase in 120-min plasma
glucose levels in both MZ (MZ1995: 7.4  4.1 vs. MZ2005:
8.5  4.7, P  0.0001) and DZ twins (DZ1995: 7.0  3.6 vs.
DZ2005: 8.4  3.9, P  0.0001). The increment in 120-min
plasma glucose levels was of similar magnitude in MZ
(1.1  2.7) and DZ (1.6  2.4) twins (P  0.22).
Cumulative concordance rates. The age-adjusted cumu-
lative proband-wise risk at age 84 years, which approxi-
mates the lifetime risk of type 2 diabetes, was similar in
MZ (0.76 [0.68–0.84]) and DZ (0.71 [0.63–0.78]) twin pairs
(Fig. 1).
Influence of zygosity and twin status on glucose
metabolism. A total of 71 singletons were included as
control subjects in the 2005 follow-up study. The singleton
control subjects were slightly younger than the twins (P 
0.004), and the distribution of sex differed significantly
between the groups of singletons and twins (P  0.006).
Therefore, adjustments were performed for sex and age in
the subsequent analyses. Adult height, weight, and BMI
were similar in twins and singletons, whereas twins were
significantly more abdominally obese with a higher WHR
than singletons (P 0.02) (Table 2). Plasma glucose levels
during the OGTT were similar in MZ and DZ twins,
whereas post-OGTT plasma glucose levels at time points
30 (P  0.05), 60 (P  0.04), and 120 (P  0.004) min were
significantly higher in twins than in singletons (Fig. 2A), as
were the incremental AUCglucose levels during the initial 30
min and the total 120 min of the OGTT. Accordingly, A1C
concentration was higher (P  0.004) in twins than
singletons, and most importantly, the prevalence of type 2
diabetes was higher in twins than in singletons (MZ: 17.5%;
DZ: 15.7%; singletons: 5.6%, P  0.03), whereas the preva-
lence of IGT was similar (MZ: 27.8%; DZ: 25.0%; singletons:
22.5%).
Plasma insulin levels were similar in twins and single-
tons before and during the OGTT, except at time point 120
min, where twins had significantly higher levels compared
with singletons (P  0.01) (Fig. 2B). Plasma C-peptide
levels were significantly increased in twins compared with
singletons at all time points, as were the incremental
AUCC-peptide levels (all P  0.001) (Fig. 2C). Twins tended
to be more insulin resistant than singletons, expressed as
the HOMA (P  0.12) and whole-body insulin sensitivity
indexes (P  0.04). Finally, systolic and diastolic blood
pressure as well as serum lipids (i.e., triglycerides, total
cholesterol, LDL cholesterol, and HDL cholesterol) were
similar in twins and singletons (data not shown).
Incidence rate of diabetes by zygosity and twin status.
The singleton control subjects exhibited a significantly
lower prevalence of type 2 diabetes subsequent to oral
glucose testing compared with twins. To determine
whether this was a true finding or merely due to selection,
we investigated incidence rates of type 2 diabetes, as
recorded in the NDR during the 10-year follow-up period.
The rate ratio of type 2 diabetes adjusted for sex and age
between the groups was 1.51 (0.93–2.44, P  0.09) for MZ
versus singletons, 1.69 (1.10–2.59, P  0.02) for DZ versus
singletons, and 1.12 (0.71–1.77, P 0.63) for MZ versus DZ.
The rate ratio between all twins and singletons was 1.62
(1.10–2.38, P  0.02). The register-based diabetes preva-
lence by the end of 2005 was 4.0% in singletons and 9.1%
(MZ: 8.2%; DZ: 9.8%) in twins (all participants in the
baseline examination, P  0.004).
DISCUSSION
We have demonstrated that elderly twins exhibit a higher
degree of abdominal obesity, glucose intolerance, and
insulin resistance, and most importantly, a higher preva-
lence and incidence rate of type 2 diabetes than singletons.
This is in accordance with the idea of pre- and early
postnatal programming as an underlying key player in the
development of the dysmetabolic syndrome later in life.
Singletons were included in the follow-up study because
of our previous observation that elderly nondiabetic twins
exhibited higher rates of hepatic glucose production (12)
compared with age-matched singletons and therefore may
be at increased risk of developing overt type 2 diabetes. In
this study, we found a higher prevalence of type 2 diabetes
in twins than singletons. Unfortunately, the methodology
does not allow mechanistic explanations of this phenom-
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FIG. 1. Age-related cumulative concordance rates (SE) for type 2 diabetes in MZ and DZ elderly twins.
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enon, although the indirect OGTT measures of insulin
resistance and secretion indicates reduced insulin sensi-
tivity in twins relative to singletons. Notably, despite the
somewhat subtle influence of twin status on OGTT plasma
insulin levels, plasma C-peptide concentrations at all time
points were increased in twins compared with singletons,
consistent with a state of compensatory increased pancre-
atic insulin secretion in the presence of a higher hepatic
insulin extraction in twins compared with singletons.
Indeed, studies have suggested an elevated hepatic extrac-
tion rate in diabetic subjects (20,21).
We have previously demonstrated significantly elevated
30-min concentrations and AUCs of plasma glucose and
insulin in MZ compared with DZ twins (11). We were able
to replicate these differences in plasma glucose profiles at
baseline in the subpopulation of MZ and DZ twins partic-
ipating in both studies. However, the 10-year follow-up
study revealed similar OGTT plasma glucose profiles in MZ
and DZ twins. The convergence of these metabolic profiles
during the 10-year follow-up period was primarily due to a
somewhat “delayed” increase in 30-min plasma glucose
levels in the DZ twins. MZ and DZ twins had similar 2-h
plasma glucose levels at baseline and follow-up and had
similar increments with advancing age. These findings
suggest that the deterioration in plasma glucose profiles
after a glucose challenge associated with advancing age
(22) may be more accelerated in MZ twins, whereas DZ
twins preserve a conspicuous degree of insulin sensitivity
to a higher age, resulting in lower postprandial glucose
profiles.
The twins participating in the follow-up study were
younger and more glucose tolerant at baseline than the
twins that were either deceased or nonparticipants. Nev-
ertheless, we demonstrated an approximately twofold
higher prevalence of type 2 diabetes in these surviving and
healthy twins compared with singleton control subjects.
Although the NDR may not be complete, there is no reason
to suspect any dissimilar or skewed recordings between
twins and singletons. The NDR incidence rates of a 60%
higher type 2 diabetes risk in twins compared with single-
tons, including all twins and spouses irrespective of par-
ticipation in follow-up study or death, indeed confirmed
the data obtained from the clinical (OGTT) examinations.
The effect of aging on the relative genetic influence on
the development of type 2 diabetes was assessed by means
of cumulative concordance rates. Interestingly, the life-
time risk of type 2 diabetes (to age 84 years) among
healthy co-twins to diabetic twins was similar in MZ and
DZ twins, suggesting that the relatively modest influence
of genetic variation on the development of type 2 diabetes
per se does not change significantly within the range of
60–80 years of age. Most interestingly, the cumulative
concordance rate (and hence recurrence risk of) type 2
diabetes of 70% in DZ twins is considerably higher than
the lifetime risk of35% (23) for first-degree relatives (i.e.,
siblings) who share the same amount of genes with their
diabetic or nondiabetic proband as DZ twins. Further-
more, the cumulative concordance rate for type 2 diabetes
to age 84 years exceeds 0.50, which represents the rate
that should be expected in DZ twins for a dominant
inherited monogenic disease. These results indeed support
that twin status per se represents a risk factor for the
development of type 2 diabetes. Although the birth
weights differed markedly between twins and singletons
(Table 2), we did not find any statistically significant
association between birth weight in the subset of twins
(n 188) or singletons (n 59) with known birth weights.
This may to some extent be due to lack of statistical power
TABLE 2
Clinical characteristics in elderly MZ and DZ twins and singletons included in the follow-up study in 2005
MZ DZ Singleton P
n (M/F) 126 (71/55) 172 (74/97) 71 (24/47) 0.006
Age at follow-up 74.4 9.5 73.7 0.5 71.4 0.7 0.004
Birth anthropometry
Weight (g) 2,656 478 2,672 459 3,513 529 0.0001
Length (cm) 46.9 3.5 48.1 2.1 51.4 2.1 0.0001
Ponderal index (g/cm3) 24.7 6.2 23.7 3.9 26.2 3.2 0.001
Adult anthropometry
Weight (kg) 73.2 13.6 72.2 12.7 71.3 12.8 0.91
Height (cm) 166.8 9.8 166.3 8.6 165.4 8.9 0.71
BMI (kg/m2) 26.3 4.7 26.1 3.9 26.1 4.1 0.97
WHR 0.92  0.09 0.89 0.10 0.86 0.09 0.02
A1C 6.0  1.0 5.8 0.7 5.6 0.3 0.004
OGTT: glucose
iAUC0–30 min 54.1 22.1 56.3 23.8 47.2 21.1 0.05
iAUC0–120 min 361.9 232.7 376.1 229.5 264.7 185.4 0.03
OGTT: insulin
iAUC0–30 min 4,410 2,871 4,004 2,830 4,331 2,827 0.32
iAUC0–120 min 33,531 18,978 32,425 22,589 31,010 19,985 0.40
OGTT: C-peptide
iAUC0–30 min 22,251 10,397 20,748 10,024 17,304 10,356 0.0001
iAUC0–120 min 222,194 80,846 214,865 81,998 162,184 90,572 0.0001
HOMA-IR 2.2 2.4 1.8 1.1 1.5 0.9 0.12
Insulin sensitivity index 15.7 8.7 16.5 7.9 19.4 8.8 0.04
HOMA-IS 64.7 43.3 63.2 35.2 56.1 25.5 0.29
Insulinogenic index 103.1 129.4 79.2 74.4 90.5 175.5 0.07
Data are means  SD. P value expresses the level of statistical significance for the comparison between the three groups (MZ, DZ, and
singletons) (ANOVA). The analyses have been adjusted for sex and age. iAUC, incremental area under curve.
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in each of the subgroups. Furthermore, it supports our
previous conclusion of the impact of fetal programming by
twin and zygosity status going beyond the impact of birth
weight per se in twins (12).
Although the BMI was similar in twins and singletons at
the clinical follow-up examination, both MZ and DZ twins
had an elevated WHR, and thereby increased abdominal
obesity, compared with the singleton control subjects.
Indeed, we and others have previously shown that low
birth weight and an adverse intrauterine environment is
associated with abdominal obesity (24,25). Abdominal
obesity is a hallmark of insulin resistance, type 2 diabetes,
and the metabolic syndrome, contributing to some un-
known extent to the documented insulin resistance and
glucose intolerance in the twins compared with singletons
in this study. The possibility remains that an accelerated
postnatal catch-up growth in the twins rather than their
documented lower birth weights per se may explain the
increased abdominal obesity in the twins. Furthermore,
other effects of twinning not directly related to fetal
growth rate including periconceptional nutrition might
theoretically explain the finding of increased abdominal
obesity and risk of type 2 diabetes in twins compared with
singletons (26).
In conclusion, twin status is evidently associated with
an increased risk of type 2 diabetes, with elderly twins
exhibiting a higher degree of abdominal obesity, glucose
intolerance, and insulin resistance and most importantly a
higher prevalence of type 2 diabetes compared with sin-
gletons. These findings together with the indication of a
predominant role of nongenetic factors in the etiology of
type 2 diabetes support the notion of pre- and early
postnatal programming as a key player in the development
of type 2 diabetes and various components of the meta-
bolic syndrome in adult life.
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tions during an OGTT in elderly MZ and DZ twins and singletons
included in the follow-up study. Data are presented as means  SD.
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